Insider Selling: Liquidia (NASDAQ:LQDA) CAO Sells 11,047 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) CAO Dana Boyle sold 11,047 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $413,489.21. Following the completion of the transaction, the chief accounting officer directly owned 156,700 shares of the company’s stock, valued at $5,865,281. This represents a 6.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Dana Boyle also recently made the following trade(s):

• On Monday, December 1st, Dana Boyle sold 303 shares of Liquidia stock. The shares were sold at an average price of $32.19, for a total value of $9,753.57.
• On Monday, October 27th, Dana Boyle sold 1,073 shares of Liquidia stock. The stock was sold at an average price of $22.93, for a total value of $24,603.89.

Liquidia Stock Up 4.1%

Liquidia stock traded up $1.49 on Tuesday, hitting $38.09. 2,055,159 shares of the stock traded hands, compared to its average volume of 2,814,845. Liquidia Corporation has a 1 year low of $11.26 and a 1 year high of $39.29. The firm has a market cap of $3.31 billion, a P/E ratio of -26.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.48. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19. The business’s fifty day simple moving average is $31.94 and its 200 day simple moving average is $25.40.

Liquidia (NASDAQ:LQDA) last released its earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The firm had revenue of $54.34 million for the quarter, compared to the consensus estimate of $18.86 million. Liquidia’s quarterly revenue was up 1106.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Liquidia Corporation will post -1.51 earnings per share for the current year.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Short interest fell materially in December — short interest declined 18.1% to 10,709,682 shares as of Dec. 31 (about 17.6% of shares were sold short) and the days-to-cover was ~11.6. Fewer active shorts can reduce downside pressure and may have contributed to the stock moving higher. (Market data entry)
• Neutral Sentiment: January short-interest data shows 0 shares as of Jan. 12 — this is almost certainly a reporting or data glitch rather than a real liquidation of all short positions. Investors should monitor the next short-interest report for a corrected figure. (Market data entry)
• Negative Sentiment: CEO Roger Jeffs sold 66,610 shares at an average $37.43 (≈$2.49M); his stake decreased ~6.03%. This large insider sale may be seen as a negative signal by some investors. SEC Filing
• Negative Sentiment: CFO Michael Kaseta sold 36,932 shares at $37.43 (≈$1.38M); his holding fell ~9.52%. SEC Filing
• Negative Sentiment: General Counsel Russell Schundler sold 27,289 shares at $37.43 (≈$1.02M); his holding fell ~4.50%. SEC Filing
• Negative Sentiment: Other insiders (including Rajeev Saggar, Jason Adair, Scott Moomaw, Sarah Krepp, CAO Dana Boyle) also executed sales on Jan. 12 at ~$37.43 per share, each reducing positions between ~6–11.7%. These combined sales represent significant insider liquidity taken at current prices. Rajeev Saggar SEC Filing Dana Boyle SEC Filing Jason Adair SEC Filing Scott Moomaw SEC Filing Sarah Krepp SEC Filing

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Raymond James Financial reiterated a “strong-buy” rating and set a $47.00 target price on shares of Liquidia in a report on Tuesday, November 4th. HC Wainwright lifted their price objective on Liquidia from $35.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. BTIG Research reissued a “buy” rating and issued a $49.00 target price on shares of Liquidia in a research note on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a report on Wednesday, October 8th. Finally, Needham & Company LLC lifted their price target on Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.67.

Institutional Trading of Liquidia

A number of institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC raised its stake in shares of Liquidia by 46.7% in the fourth quarter. SG Americas Securities LLC now owns 54,696 shares of the company’s stock worth $1,886,000 after purchasing an additional 17,407 shares during the last quarter. Insight Wealth Strategies LLC purchased a new stake in shares of Liquidia during the fourth quarter valued at $4,891,000. Tudor Investment Corp ET AL bought a new stake in Liquidia in the 3rd quarter worth about $1,536,000. FNY Investment Advisers LLC purchased a new position in Liquidia in the 3rd quarter worth about $34,000. Finally, Caxton Associates LLP bought a new position in Liquidia during the 3rd quarter valued at about $389,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).